To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(7 sites)

Taiwan

Taipei Veterans General Hospital, Taipei, Beitou District

National Taiwan University Cancer Center, Taipei, Da'an Dist.

Linkou Chang Gung Memorial Hospital, Taoyuan District, Guishan Dist.

Tri-Service General Hospital, Taipei, Neihu District

Shuang Ho Hospital, New Taipei City, Zhonghe District

National Taiwan University Hospital, Taipei, Zhongzheng Dist.

Taichung Veterans General Hospital, Taichung